BioSpace News Archive

Onconova Therapeutics, Inc. announced that Onconova and collaborators will present a preclinical poster related to its lead program, narazaciclib, at the 65th American Society for Hematology Annual Meeting & Exposition, taking place in San Diego, California from December 9 to 12, 2023.

Pfizer Inc. will present its latest data showcasing advances in the treatment of hemophilia, sickle cell disease, and blood cancers at the 65th American Society of Hematology Annual Meeting and Exposition in San Diego from December 9-12.

Kane Biotech Inc. in partnership with ProgenaCare Global LLP announces the launch of the newly rebranded revyve™ Antimicrobial Wound Gel.

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) will report its third quarter 2023 financial results on Thursday, November 9, 2023. Amylyx’ senior management team will host a conference call and audio webcast at 8:00 a.m. ET to discuss the financial results and other company updates.

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its third quarter 2023 financial results and operational highlights at 8:30 a.m. Eastern Standard Time (EST) on Thursday, November 9, 2023.

Otsuka Pharmaceutical Development & Commercialization, Inc. and Visterra Inc., today announced that the full results of a Phase 2 trial of sibeprenlimab (VIS649) for treatment of immunoglobulin A nephropathy (IgAN; Berger’s disease) have been published in the New England Journal of Medicine.

Assertio Holdings, Inc. announced that it will release third quarter 2023 financial results on Wednesday, November 8, 2023, after the market close.

Seagen Inc. (NASDAQ: SGEN) today announced that 12- and 24-month progression free survival data will be presented for an ADCETRIS® (brentuximab vedotin) and immunotherapy combination in early and advanced stage classical Hodgkin lymphoma (cHL), respectively.

Maxwell Biosciences, Inc., (MXB) a pre-clinical drug platform company focused on developing biomimetic therapeutics that improve upon natural immune system peptides based on its patented Claromer® technology platform

NovalGen Ltd (“NovalGen”), a biopharmaceutical company developing breakthrough immunotherapies, alongside an Autoregulation platform, today announces the online publication of two abstracts submitted to the American Society of Hematology Annual meeting, to be held December 9-12, 2023 in San Diego, USA.